Eric Churchill

  • Citations Per Year
Learn More
Most non-Hodgkin's lymphomas (NHL) initially respond to chemotherapy, but relapse is common and treatment is often limited by chemotherapy-related toxicity. Bortezomib, is a highly selective proteasome inhibitor with anti-NHL activity; it is currently FDA approved for second-line treatment of mantle cell lymphoma (MCL). Bortezomib exerts its activity in(More)
A considerable amount of work has been reported on the surface-active cations, and several workers have shown that, although these compounds are highly germicidal, they are also highly bacteriostatic in relatively high dilutions. Although these compounds are highly bacteriostatic, there has been little work done to distinguish between actual germicidal(More)
  • 1